Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14403358 | 1.00 | TDP1 (0.39) | TDP1CA2NAMPTCES2CYP3A4 | |
| SCHEMBL8390457 | 1.00 | TDP1 (0.39) | TDP1CA2NAMPTCES2CYP3A4 | |
| SCHEMBL8390936 | 0.98 | TDP1 (0.41) | TDP1CA2NAMPTCES2CYP3A4 | |
| SCHEMBL11956756 | 0.93 | TDP1 (0.38) | TDP1NAMPTCES2TSHRALDH1A1 | |
| SCHEMBL19170656 | 0.84 | TDP1 (0.41) | TDP1CES2CYP3A4TSHRALDH1A1 | |
| SCHEMBL7243144 | 0.82 | MEN1 (0.50) | TDP1CES2CYP3A4TSHRALDH1A1 | |
| SCHEMBL22856291 | 0.82 | CES2 (0.52) | TDP1CES2TSHRALDH1A1 | |
| SCHEMBL15223140 | 0.82 | TDP1 (0.39) | TDP1CA2CYP3A4ABCB11ADRA2B | |
| SCHEMBL20317552 | 0.80 | CES2 (0.50) | TDP1CES2CYP3A4TSHRALDH1A1 | |
| SCHEMBL16421150 | 0.80 | TDP1 (0.38) | TDP1CES2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | TDP1 2137/4885CA2 4176/4885NAMPT 4168/4885 |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | TDP1 1896/4885CA2 2225/4885NAMPT 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.